Myeloma follow-up after treatment in China: tests, prescriptions and continuing care at home

Leaving the treating hospital does not usually end myeloma care. Maintenance, laboratory monitoring, renal and skeletal management, and recovery after transplant or immune therapy may continue. Agreeing on responsibilities before departure reduces gaps after returning home. This guide, checked in September 2026, explains how to turn discharge advice into a locally deliverable follow-up plan.

Key takeaways

These excerpts come from the original article. Read the full sections below for context.

A discharge summary describes completed treatment, but responsibility for interpreting the next abnormal result, renewing a prescription or pausing therapy must also be clear. Identify the home hematologist before return and provide the actual regimen, response and complications. Confirm whether the Chinese team offers continuing remote follow-up and its scope; a contact address alone does not establish an ongoing prescribing service.
Renal improvement does not remove the need to monitor function, electrolytes, drug suitability and contributing problems. Patients receiving dialysis should transfer the modality, schedule, vascular-access and recent prescription information, with a receiving service arranged before travel. Reduction or cessation of dialysis requires renal assessment rather than inference from falling light chains. The IMWG renal recommendations support continuing individualized review.
Keep a concise timeline of visits, results, prescription changes, infections, transfusions and important symptoms. Date the latest medication list so that different clinicians do not act on different versions. Home records should focus on information relevant to decisions, such as temperature, function or requested blood-pressure measurements, rather than indiscriminate testing.

Quick answer

Full guide

Name the clinician responsible for the next decision

A discharge summary describes completed treatment, but responsibility for interpreting the next abnormal result, renewing a prescription or pausing therapy must also be clear. Identify the home hematologist before return and provide the actual regimen, response and complications. Confirm whether the Chinese team offers continuing remote follow-up and its scope; a contact address alone does not establish an ongoing prescribing service.

Follow-up priorities differ after induction, during transplant recovery, on maintenance and during relapse treatment. The EHA–EMN guideline provides the wider framework. The handover should identify the current phase, next objective and unresolved decisions so that the receiving clinician can continue care without reconstructing the original intent.

Monitor the features that measure this patient's disease

Follow-up commonly combines blood counts, renal function, calcium, monoclonal protein and free light chains, with the exact selection reflecting the original illness. Light-chain, low-secretory or extramedullary disease cannot always be followed adequately with electrophoresis alone. Ask which measures are most informative and when imaging or marrow assessment is needed. The NICE myeloma recommendations link testing to clinical assessment.

Write down the first appointment after return and the expected later schedule, including symptoms that require an earlier visit. Early recovery or prescription changes may need closer review than stable later follow-up. Another patient's interval is not necessarily appropriate, and the next appointment should not wait until every remaining tablet has been used.

Make results from different laboratories comparable

Keep values, units, reference ranges and methods when changing laboratories. A protein or light-chain change may need confirmation and trend review rather than immediate labeling as relapse. Provide key results from before treatment in China, best response and discharge as reference points.

Daratumumab can interfere with immunofixation interpretation, so the home laboratory should know the product and administration dates. The original interference study explains the potential confusion between therapeutic antibody and residual protein. Retain the complete result rather than removing a small unexpected band or omitting the treatment history.

MRD negativity still requires a surveillance plan

MRD reflects a defined method, sensitivity and sampling situation, rather than permanent cure. The team should specify whether repeating it is useful, which method will be used and how it affects decisions. It should not automatically mean a marrow procedure at every visit. The IMWG response and MRD standards explain the definitions and limitations.

If a maintenance change is planned, the receiving physician needs its full rationale and surveillance requirements. The 2026 ENDURANCE study added evidence for fixed two-year maintenance in selected standard-risk patients without upfront transplant; it does not create one stopping rule for everyone. The original ENDURANCE report must be matched to the treatment pathway. A single negative result or temporary lack of supply is not a reason for independent cessation.

Verify continuing prescriptions before departure

Confirm generic medicines, formulation, route, cycle calendar and the last dose actually given. Establish that the home physician can prescribe and that a legal supply route exists. Similar brand names do not guarantee identical formulations, and oral and injected therapies have different storage and administration needs. A Chinese prescription should not be assumed to be accepted by every pharmacy abroad.

The National Health Commission anticancer guidance can help identify the Chinese treatment and indication context, but cannot resolve another country's supply and payment rules. If continuity is doubtful, discuss alternatives while choosing the regimen. Do not combine missed doses; a prolonged gap in an injectable treatment may require reassessment before restarting.

Continue renal care according to the established findings

Renal improvement does not remove the need to monitor function, electrolytes, drug suitability and contributing problems. Patients receiving dialysis should transfer the modality, schedule, vascular-access and recent prescription information, with a receiving service arranged before travel. Reduction or cessation of dialysis requires renal assessment rather than inference from falling light chains. The IMWG renal recommendations support continuing individualized review.

Identify medicines needing adjustment as renal function changes, together with personal advice on fluids and analgesics. Reduced urine, swelling, persistent vomiting or rapidly worsening results warrant earlier care. These problems should not be left until a future international online consultation merely because the inpatient phase has finished.

Review skeletal recovery separately from protein response

Bone defects, vertebral collapse and muscle weakness can remain after laboratory improvement. Continue weight-bearing, brace and rehabilitation advice, increasing activity appropriately. Tumor response does not confirm that bone strength is restored. The home team should also review bone-protective treatment, dental care and any stopping strategy. The IMWG bone recommendations provide the management background.

Record walking distance, transfers, stairs, analgesic use and falls. New focal pain may arise from fracture or active disease and requires assessment rather than assumption. Back pain accompanied by weakness, numbness or bladder and bowel changes needs urgent care, not simply more analgesia and observation.

Infection prevention and hepatitis B care may continue

The duration of antivirals, other prophylaxis and immunoglobulin management depends on treatment and recovery. After bispecific or cellular therapy, feeling well does not necessarily mean immunity has normalized. The bispecific infection consensus explains continuing risk and monitoring requirements.

Where hepatitis B risk is relevant, specify antiviral treatment, viral monitoring and the clinician responsible. The last anticancer dose should not automatically become the end date for all preventive care. The ASCO hepatitis B guidance supports a defined plan. Vaccination should also reflect the actual treatment history rather than a routine schedule adopted independently while immunocompromised.

Make delayed cellular-therapy risks visible to the home team

An uncomplicated early observation period does not exclude later cytopenias, infection, neurological changes or other effects. The summary should identify the cellular product, infusion date, previous toxicity and long-term monitoring requirements. Relatives should report changes in communication, behavior or mobility rather than focusing solely on protein results.

After cilta-cel, severe or prolonged diarrhea, abdominal pain and weight loss can occur as part of immune effector cell-associated enterocolitis weeks to months after infusion. The FDA safety communication describes the boxed warning added in 2025. Patients do not need to diagnose it themselves, but should disclose the treatment history so that persistent symptoms receive appropriate assessment.

Know when to seek care before the scheduled review

Fever, chills, marked breathing difficulty or rapid decline during treatment or immune recovery needs prompt local contact. Severe chest pain, persistent bleeding, altered awareness, suspected fracture or spinal-compression symptoms may require emergency assessment. The NCI infection information emphasizes the urgency of some treatment-associated infections. Waiting for an unanswered remote message is not an adequate emergency plan.

For laboratory changes without an immediate emergency, send the full trend and symptoms through the agreed route. The clinician may confirm progression with repeat testing or act sooner because of rapid change or previous organ injury. Do not replace treatment using an online regimen, but do not assume that every minor fluctuation requires another admission in China either.

Maintain a record that remains useful over time

Keep a concise timeline of visits, results, prescription changes, infections, transfusions and important symptoms. Date the latest medication list so that different clinicians do not act on different versions. Home records should focus on information relevant to decisions, such as temperature, function or requested blood-pressure measurements, rather than indiscriminate testing.

Plan for local prescriptions, investigations, supportive care and further specialist review. The Chinese admission bill is not necessarily the financial endpoint of the course. Discuss supply or affordability problems early enough to arrange an alternative instead of interrupting treatment silently. Sustainable follow-up gives the response obtained during treatment a better opportunity to translate into a more stable daily life.